ArticleLancet (London, England)2011
Vaccine production, distribution, access, and uptake.
Article in Lancet (London, England), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review and meta-analysis of strategies to promote vaccination uptake.Nature human behaviour · 2024Pooled it
- Disparities in Seasonal Influenza Vaccination in Europe.Immunity, inflammation and disease · 2025Review
- 3C protease-independent production of foot-and-mouth disease virus-like particles in Pichia pastoris.Applied microbiology and biotechnology · 2025Article
- Production of an immunogenic trivalent poliovirus virus-like particle vaccine candidate in yeast using controlled fermentation.NPJ vaccines · 2025Article
- Uptake of Influenza Vaccine among Older Adults with Cardiovascular Comorbidities.Arquivos brasileiros de cardiologia · 2025Article
- Advances and Challenges inVaccines · 2025Review
- Evaluation of the immune effect of foot-and-mouth disease virus-like particles derived fromFrontiers in microbiology · 2025Article
- Routine immunization againstThe Lancet regional health. Southeast Asia · 2024Article
- Review
- The Implications of Artificial Intelligence on Infection Prevention and Control: Current Progress and Future Perspectives.China CDC weekly · 2024Article
- Thermostable vacuum foam dried Newcastle disease vaccine: Process optimization and pilot-scale study.Applied microbiology and biotechnology · 2024Article
- Analytical Insights into Protein-Alum Interactions and Their Impact on Conformational Epitope.Pharmaceutics · 2024Article
- Extracellular vesicle depletion and UGCG overexpression mitigate the cell density effect in HEK293 cell culture transfection.Molecular therapy. Methods & clinical development · 2024Article
- SARS-CoV-2 IgG antibody status in unvaccinated and 2-dose vaccinated Indonesians by AstraZeneca.Journal of public health in Africa · 2023Article
- Ocular Inflammation Post-Vaccination.Vaccines · 2023Review
- COVID-19 vaccine incentive scheduling using an optimally controlled reinforcement learning model.Physica D. Nonlinear phenomena · 2023Article
- Protease-Independent Production of Poliovirus Virus-like Particles in Pichia pastoris: Implications for Efficient Vaccine Development and Insights into Capsid Assembly.Microbiology spectrum · 2023Article
- Maturation of Aluminium Adsorbed Antigens Contributes to the Creation of Homogeneous Vaccine Formulations.Vaccines · 2023Article
- Internal and external factors affecting vaccination coverage: Modeling the interactions between vaccine hesitancy, accessibility, and mandates.PLOS global public health · 2023Article
- Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
3 authors.
Funding
Abstract
For human vaccines to be available on a global scale, complex production methods, meticulous quality control, and reliable distribution channels are needed to ensure that the products are potent and effective at the point of use. The technologies used to manufacture different types of vaccines can strongly affect vaccine cost, ease of industrial scale-up, stability, and, ultimately, worldwide availability. The complexity of manufacturing is compounded by the need for different formulations in different countries and age-groups. Reliable vaccine production in appropriate quantities and at affordable prices is the cornerstone of developing global vaccination policies. However, to ensure optimum access and uptake, strong partnerships are needed between private manufacturers, regulatory authorities, and national and international public health services. For vaccines whose supply is insufficient to meet demand, prioritisation of target groups can increase the effect of these vaccines. In this report, we draw from our experience of vaccine development and focus on influenza vaccines as an example to consider production, distribution, access, and other factors that affect vaccine uptake and population-level effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.